No Carolina / NY / Florida
Ph: 561.316.3330

Florida / New York / No Carolina
Ph: 561.316.3330

New US Headquarters Opened By Mass Photometry Pioneers Refeyn

Refeyn staff join mass photometry inventor Prof. Philipp Kukura in cutting ribbon to Refeyn’s new US customer interaction center in Massachusetts’ Waltham Biotech Hub

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Summation

  • The US HQ grand opening followed the successful third annual Mass Photometry Summit 2024, which supported customers by bringing together mass photometry users to share their experiences and how they are pushing the limits of the technology in their own research to provide vital insights for scientific discovery.

Refeyn, the company behind pioneering mass photometry technologies, has officially opened its new 10,000 sq. ft. US Headquarters and Customer Interaction Center in Waltham’s Biotech Hub in Greater Boston, Massachusetts. Refeyn CEO Gerry Mackay – along with two members of the sales team and one of the company’s co-founders, Philipp Kukura – helped to cut the ribbon at the opening event. Philipp Kukura led the research team that invented mass photometry, a unique light-based bioanalytical tool for rapid, single-particle analysis. The ceremony was attended by senior representatives from neighboring biotech companies in the Boston area, as well as Refeyn customers and employees.

The grand opening is a significant milestone in the rapid growth of Refeyn since it was spun out of Oxford University just six years ago. Hundreds of its instruments are now used globally for applications in scientific discovery, R&D, and therapeutics production, with more applications being cited regularly. As Philipp Kukura commented at the opening event, “In the early days, mass photometry’s potential was obvious and the key question wasn’t ‘What can mass photometry do?’ but ‘What can mass photometry not do?’ It is amazing to witness the opening of Refeyn’s state-of-the-art US HQ today, having started in an early 19th century building above a burger joint in central Oxford, which feels like only yesterday.”

Gerry Mackay, CEO at Refeyn, said,

“With the opening of our new US HQ, the success of Refeyn and mass photometry is evident as we now have over 180 employees globally and are currently recruiting more to support our expanding US customer-base from our new facility. Furthermore, with over 300 scientific papers to date citing mass photometry, this literature highlights the ever-growing capabilities of this unique technology as it is increasingly adopted in life science laboratories around the world.”

Serving as Refeyn’s US Customer Interaction Center, alongside offices, meeting and training rooms, the leading-edge laboratory space in the new HQ now enables customers across North America to visit to run samples and test applications. Refeyn is working to achieve sustainability certification for this laboratory space, which includes a BSL-2 lab, service center, R&D center and applications lab. The new site also facilitates instrument maintenance, customer training sessions, and workshops that all serve to ensure excellence in support for Refeyn’s customers across North America and beyond.

The US HQ grand opening followed the successful third annual Mass Photometry Summit 2024, which supported customers by bringing together mass photometry users to share their experiences and how they are pushing the limits of the technology in their own research to provide vital insights for scientific discovery. Refeyn scientists also shared developments in applications and products and gave demonstrations.

From investigating oligomerization and macromolecular assembly to analyzing adeno-associated viruses (AAVs), users’ presentations and posters highlighted much of what mass photometry can do – and how users are driving it even further. Presenters included Dr. Di Wu of the National Institutes of Health, an early adopter of mass photometry, who talked about SEC-MP, a technique for AAV characterization for gene therapy that he and colleagues published in 2023. The day’s keynote speaker was Prof. Priyamvada Acharya from Duke University School of Medicine, whose work focuses on the HIV-1 envelope.

To find out more about Refeyn and mass photometry, please visit: https://www.refeyn.com

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

SOPHiA GENETICS Launches New Residual Acute Myeloid (RAM) Application

Philippe Menu, M.D., PhD., Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS. "We are proud to contribute to the fight against AML through our SOPHiA DDM™ RAM Solution. In particular we feel that the capability to seamlessly track longitudinally the evolution of individual mutations over time through a dedicated add-on module of our SOPHiA DDM™ Platform has the potential to be a game-changer for clinical researchers."

Aurion Biotech Receives Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for Its Drug Candidate AURN001

Sterling Chung, Vice President of Regulatory Affairs and Quality at Aurion Biotech. “These designations underscore the importance of developing a potential solution for millions of patients around the world who suffer from corneal endothelial diseases. We look forward to working closely with the FDA to expedite the development of our cell therapy.”

Golidocitinib Approved in China as First-in-class JAK1 Only Inhibitor for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor approved for the treatment of r/r PTCL based on results from the multinational pivotal JACKPOT8B study.

By using this website you agree to accept Medical Device News Magazine Privacy Policy